Psoriasis Clinical Trial

Long-Term Safety and Efficacy of Imsidolimab (ANB019) in Subjects With Generalized Pustular Psoriasis

Summary

This is a Phase 3, long term extension study to evaluate the safety and efficacy of imsidolimab compared with placebo in adult subjects with generalized pustular psoriasis (GPP).

View Full Description

Full Description

This study will also evaluate the pharmacokinetic (PK) profile of imsidolimab and explore the immunogenicity of imsidolimab in subjects with GPP

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Subject participated in the preceding placebo-controlled Phase 3 study ANB019-301 and completed at least the Week 1 visit of the ANB019-301 study without the use of rescue/prohibited medication for GPP
Subject must be a candidate for prolonged GPP treatment according to the Investigator's judgment

Exclusion Criteria:

Use of prohibited medications between the last visit of the ANB019-301 study and the Day 1 visit of the ANB019-302 study.

Study is for people with:

Psoriasis

Phase:

Phase 3

Estimated Enrollment:

42

Study ID:

NCT05366855

Recruitment Status:

Active, not recruiting

Sponsor:

AnaptysBio, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 5 Locations for this study

See Locations Near You

Site 109
Largo Florida, 33771, United States
Site 105
Louisville Kentucky, 40056, United States
Site 10-101
Ann Arbor Michigan, 48108, United States
Site 101
Ann Arbor Michigan, 48108, United States
Site 108
Dallas Texas, 75061, United States
Site 102
Springville Utah, 84663, United States
Site 35-101
Melbourne , , Australia
Site 35102
Sydney , , Australia
Site 16-102
Nantes , , France
Site 16-101
Paris , , France
Site 59104
Batumi , , Georgia
Site 59-101
Tbilisi , , Georgia
Site 59-105
Tbilisi , , Georgia
Site 59102
Tbilisi , , Georgia
Site 59103
Tbilisi , , Georgia
Site 17102
Bensheim , , Germany
Site 17104
Bonn , , Germany
Site 17103
Hanau , , Germany
Site 17105
Würzburg , , Germany
Site 45101
Pusan , , Korea, Republic of
Site 45102
Seoul , , Korea, Republic of
Site 45103
Seoul , , Korea, Republic of
Site 45104
Seoul , , Korea, Republic of
Site 42104
Cheras , , Malaysia
Site 42-107
Johor Bahru , , Malaysia
Site 42106
Johor Bahru , , Malaysia
Site 42105
Kota Bharu , , Malaysia
Site 42-110
Kuala Lumpur , , Malaysia
Site 42101
Kuala Lumpur , , Malaysia
Site 42102
Muar , , Malaysia
Site 42-108
Pulau Pinang , , Malaysia
Site 42103
Putrajaya , , Malaysia
Site 42-109
Selayang Baru Utara , , Malaysia
Site 64-102
Casablanca , , Morocco
Site 64-103
Casablanca , , Morocco
Site 64-101
Oujda , , Morocco
Site 30104
Kraków , , Poland
Site 30103
Ossy , , Poland
Site 30101
Rzeszów , , Poland
Site 30102
Wrocław , , Poland
Site 30105
Łódź , , Poland
Site 31-102
Bucuresti , , Romania
Site 31-101
Cluj-Napoca , , Romania
Site 31-103
Iaşi , , Romania
Site 24-101
Barcelona , , Spain
Site 24-104
Las Palmas De Gran Canaria , , Spain
Site 24-102
Madrid , , Spain
Site 24-103
Madrid , , Spain
Site 24-105
Valencia , , Spain
Site 63101
Kaohsiung , , Taiwan
Site 63102
Taipei , , Taiwan
Site 63103
Taipei , , Taiwan
Site 64104
Taipei , , Taiwan
Site 46101
Bangkok , , Thailand
Site 46102
Chiang Mai , , Thailand
Site 46104
Khon Kaen , , Thailand
Site 46103
Pathum Thani , , Thailand
Site 62-101
Sfax , , Tunisia
Site 62-102
Sousse , , Tunisia
Site 62-103
Tunis , , Tunisia
Site 33-101
Ankara , , Turkey
Site 33-103
Antalya , , Turkey
Site 33-105
Istanbul , , Turkey
Site 33-106
Istanbul , , Turkey
Site 33-107
Istanbul , , Turkey
Site 33-102
Kayseri , , Turkey
Site 33-104
Nilüfer , , Turkey

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Phase:

Phase 3

Estimated Enrollment:

42

Study ID:

NCT05366855

Recruitment Status:

Active, not recruiting

Sponsor:


AnaptysBio, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.